Presented by Jeannie Gorman, MS, CCN | June 3, 2026 at 12 PM Pacific

This webinar will explore how the GI360™ provides a comprehensive view of the microbiome and dysbiosis, with insights into GLP-1 signaling pathways. Learn practical applications for patients with GI, autoimmune, cardiovascular, neurological, or skin conditions, and discover how stool insights can guide better clinical outcomes.

Learning Objectives:

• This session will describe the comprehensive, integrated GI360™ methodologies and their clinical applications.
• We will identify appropriate candidates for stool testing, including patients on or initiating GLP-1 agonist therapy.
• We will review how GLP-1 use and metabolic dysfunction may relate to reduced microbial diversity, SCFA production, and altered gut-metabolic signaling.
• We will interpret dysbiosis and GLP-1-modulating bacterial patterns in relation to appetite regulation and metabolic response.
• We will discuss targeted interventions (diet, fiber, probiotics, and dysbiosis therapies) to support microbiome and GLP-1 signaling and the role of retesting in monitoring microbiome and metabolic outcomes over time.

Presented by Ruth Hobson, ND | July 1, 2026 at 12 PM Pacific

ADHD is significantly underdiagnosed in women, many of whom are not identified until adulthood, often around age 36 to 38, largely due to gender biased symptom recognition and limited awareness of how hormonal changes across the female lifespan impact the condition. Estrogen plays a central role in regulating dopamine and serotonin, making women particularly vulnerable to symptom fluctuations during puberty, menstruation, postpartum, and perimenopause. Declining estrogen can worsen inattention, impulsivity, and emotional instability through reduced dopamine availability.

Growing research also points to the gut brain axis as a factor in ADHD, with gut microbiota influencing neurotransmitter production and brain function. Dysbiosis has been linked to greater symptom severity, driving interest in integrative approaches such as probiotics, dietary interventions, and microbiome focused care.

With diagnoses among adult women rising sharply, primary care providers are well positioned to close the recognition gap. This presentation equips clinicians with practical, evidence based tools integrating hormonal, neurochemical, and gut health perspectives to support more accurate diagnoses and individualized care.

Learning Objectives:

• Identify key factors in making an ADHD diagnosis and factors that may contribute to a delayed presentation of ADHD in female patients
• Explain the relationship between estrogen and neurotransmitter function, particularly the modulation of dopamine and serotonin, and how fluctuations in these systems influence ADHD symptoms.
• Describe the role of the gut-brain axis and microbiome in ADHD pathophysiology, including how dysbiosis can contribute to neuroinflammation and neurotransmitter imbalance.
• Assess ADHD symptoms in women within the context perimenopause
• Apply integrative approaches in primary care to support female patients with ADHD, including nutritional interventions, adaptogens, probiotics, and lifestyle modifications.

Presented by Dan Kalish, DC | July 7, 2026 at 12 PM Pacific

Estrogen balance is shaped by more than hormone production. It also depends on gut microbiome health, liver detoxification, and the body's ability to properly eliminate or recycle estrogen.

This class explains how the estrobolome influences estrogen metabolism, how Phase II liver detoxification prepares estrogen for excretion, and how gut dysbiosis and beta-glucuronidase activity can lead to excess estrogen recycling and hormone-related symptoms.

Learning Objectives:

• Understand the role of the estrobolome in estrogen regulation.
• Map the connection between liver detoxification, gut excretion, and estrogen recycling.
• Learn how beta-glucuronidase can reactivate estrogen for reabsorption.
• Recognize how gut dysbiosis may contribute to estrogen dominance.
• Identify key stool and hormone biomarkers related to estrogen clearance